Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership0 shares
Ownership 0.00%
Vanguard Group Inc ownership in TVTX / Travere Therapeutics, Inc.

2026-03-27 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Travere Therapeutics, Inc. (US:TVTX). This represents 0.0 percent ownership of the company. In their previous filing dated 2025-07-29 , Vanguard Group Inc had reported owning 5,994,283 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-03-27 2026-03-27 13G/A 5,994,283 0 -100.00 0.00 -100.00
2025-07-29 2025-07-29 13G/A 5,014,020 5,994,283 19.55 6.74 19.29
2025-04-30 2025-04-30 13G/A 6,742,165 5,014,020 -25.63 5.65 -27.10
2025-01-31 2025-01-31 13G/A 6,902,150 6,742,165 -2.32 7.75 -14.08
2024-11-12 2024-11-12 13G/A 6,902,150 6,902,150 0.00 9.02 0.00
2024-11-04 2024-11-04 13G/A 5,515,143 6,902,150 25.15 9.02 22.89
2024-02-13 2024-02-13 13G/A 3,515,446 5,515,143 56.88 7.34 33.94
2023-02-09 2023-02-09 13G/A 3,880,873 3,515,446 -9.42 5.48 -13.56
2022-02-10 2022-02-10 13G/A 3,404,443 3,880,873 13.99 6.34 -4.95
2021-02-10 2021-02-10 13G/A 2,523,335 3,404,443 34.92 6.67 13.63
2020-02-11 2020-02-11 13G 2,523,335 5.87

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 6,309,229 -304,139 -4.60 241,076 52.52 0.0035
2025-11-07 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 6,613,368 619,085 10.33 158,059 78.16 0.0024
2025-08-11 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 5,994,283 980,263 19.55 88,715 -1.26 0.0014
2025-05-09 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 5,014,020 -1,728,145 -25.63 89,851 -23.50 0.0016
2025-02-11 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 6,742,165 -159,985 -2.32 117,449 21.63 0.0020
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 6,902,150 282,394 4.27 96,561 77.46 0.0017
2024-08-13 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 6,619,756 353,927 5.65 54,414 12.64 0.0010
2024-05-10 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 6,265,829 750,686 13.61 48,310 -2.57 0.0010
2024-03-11 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 5,515,143 847,685 18.16 49,581 18.82 0.0011
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 5,515,143 847,685 49,581 0.0009
2023-12-18 2023-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 4,667,458 460,176 10.94 41,727 -35.43 0.0010
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,667,458 460,176 41,727 0.0002
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,207,282 222,688 5.59 64,624 -27.89 0.0015
2023-07-14 2023-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 3,984,594 469,148 13.35 89,614 21.21 0.0023
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,984,594 469,148 89,614 0.0005
2023-02-10 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,515,446 133,836 3.96 73,930 -11.27 0.0020
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,381,610 50,791 1.52 83,323 3.24 0.0025
2022-08-12 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,330,819 -516,716 -13.43 80,707 -18.60 0.0023
2022-05-13 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,847,535 -33,338 -0.86 99,152 -17.69 0.0023
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,880,873 15,392 0.40 120,462 28.51 0.0027
2021-11-12 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,865,481 30,725 0.80 93,738 67.54 0.0023
2021-08-13 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,834,756 -166,832 -4.17 55,949 -44.01 0.0014
2021-05-14 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,001,588 597,145 17.54 99,920 7.69 0.0027
2021-02-12 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 3,404,443 181,611 5.64 92,788 55.96 0.0027
2020-11-16 2020-09-30 13F RETROPHIN COM 761299106 3,222,832 251,988 8.48 59,494 -1.88 0.0020
2020-08-14 2020-06-30 13F RETROPHIN COM 761299106 2,970,844 396,250 15.39 60,636 61.42 0.0022
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 2,574,594 51,259 2.03 37,563 4.83 0.0016
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 2,523,335 156,639 6.62 35,831 30.63 0.0012
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 2,366,696 174,694 7.97 27,430 -37.71 0.0010
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 2,192,002 73,736 3.48 44,036 -8.14 0.0017
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 2,118,266 91,878 4.53 47,937 4.54 0.0019
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 2,026,388 97,786 5.07 45,857 -17.24 0.0021
2018-12-13 2018-09-30 13F/A-2 RETROPHIN COM 761299106 1,928,602 26,016 1.37 55,409 6.83 0.0022
2018-11-23 2018-09-30 13F/A-1 RETROPHIN COM 761299106 1,928,602 0 55,409 0.0022
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 1,928,602 26,016 55,409
2018-08-14 2018-06-30 13F RETROPHIN COM 761299106 1,902,586 134,701 7.62 51,865 31.20 0.0022
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 1,767,885 64,595 3.79 39,531 10.15 0.0017
2018-02-14 2017-12-31 13F RETROPHIN COM 761299106 1,703,290 16,446 0.97 35,888 -14.52 0.0016
2017-11-14 2017-09-30 13F RETROPHIN COM 761299106 1,686,844 51,610 3.16 41,986 32.42 0.0020
2017-08-24 2017-06-30 13F/A-1 RETROPHIN COM 761299106 1,635,234 125,695 8.33 31,707 13.78 0.0016
2017-08-11 2017-06-30 13F RETROPHIN COM 761299106 1,635,234 125,695 31,707
2017-05-12 2017-03-31 13F RETROPHIN COM 761299106 1,509,539 102,833 7.31 27,866 4.65 0.0014
2017-02-14 2016-12-31 13F RETROPHIN COM 761299106 1,406,706 74,223 5.57 26,629 -10.70 0.0015
2016-11-14 2016-09-30 13F RETROPHIN COM 761299106 1,332,483 76,907 6.13 29,820 33.35 0.0018
2016-08-10 2016-06-30 13F RETROPHIN COM 761299106 1,255,576 69,097 5.82 22,362 37.98 0.0014
2016-05-13 2016-03-31 13F RETROPHIN COM 761299106 1,186,479 16,028 1.37 16,207 -28.22 0.0011
2016-02-08 2015-12-31 13F RETROPHIN COM 761299106 1,170,451 19,152 1.66 22,578 -3.20 0.0015
2015-11-12 2015-09-30 13F/A-1 RETROPHIN COM 761299106 1,151,299 113,702 10.96 23,325 -32.19 0.0010
2015-11-12 2015-09-30 13F/A-1 RETROPHIN COM 761299106 1,151,299 113,702 23,325 0.0010
2015-08-13 2015-06-30 13F RETROPHIN COM 761299106 1,037,597 316,464 43.88 34,396 99.06 0.0023
2015-05-15 2015-03-31 13F/A-1 RETROPHIN COM 761299106 721,133 81,451 12.73 17,279 120.71 0.0012
2015-05-14 2015-03-31 13F RETROPHIN COM 761299106 721,133 17,279
2015-02-12 2014-12-31 13F RETROPHIN COM 761299106 639,682 232,663 57.16 7,829 113.21 0.0006
2014-11-12 2014-09-30 13F RETROPHIN COM 761299106 407,019 81,958 25.21 3,672 -3.77 0.0003
2014-08-11 2014-06-30 13F RETROPHIN COM 761299106 325,061 49,979 18.17 3,816 -34.78 0.0003
2014-05-13 2014-03-31 13F RETROPHIN COM 761299106 275,082 275,082 5,851 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.